Cellular Therapy Option for Treatment of Central Nervous System EBV-PTLD
Susan Prockop, MD, discusses an option available for the treatment of central nervous Epstein-Barr virus-positive posttransplant lymphoproliferative disease.<br />
Susan Prockop, MD, associate attending in pediatrics at Memorial Sloan Kettering Cancer Center, discusses an option available for the treatment of central nervous system (CNS) Epstein-Barr virus (EBV)-positive posttransplant lymphoproliferative disease (PTLD).
According to a subset analysis, patients are at very high risk of developing this disease after hematopoietic stem cell transplant or solid organ transplant and the modalities available are still limited, Prockop says. A high dose of radiation can be debilitating with significant side effects, so adoptive immunotherapy with EBV-specific T cells is a good option for these patients.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
